Latest Aspergillosis & Related Research Updates (Week 4).

Executive overview (what stands out this fortnight)

Key signals

• Immune dysregulation—not just classic immunosuppression—continues to emerge as a central driver of invasive aspergillosis.

• Allergic bronchopulmonary aspergillosis (Allergic Bronchopulmonary Aspergillosis) is appearing in atypical and early phenotypes, including absence of bronchiectasis.

• Antifungal toxicity and pharmacokinetic variability remain clinically important.

• Paediatric invasive aspergillosis evidence is improving.

• Environmental and One Health studies continue to inform exposure risk.

• Overlap with non-tuberculous mycobacteria and microbiome disruption is increasingly evident.

---

1. Immunocompromise, viral infection, and invasive aspergillosis
Immunocompromise and early-onset invasive pulmonary aspergillosis in viral pneumonia

Sun B et al., Frontiers in Public Health, 2026

Relevance

• Directly informs understanding of early invasive pulmonary aspergillosis in severe viral pneumonia.
• Extends COVID-associated pulmonary aspergillosis concepts to non-COVID viral infections.

Key points

• Viral pneumonia causes early immune dysregulation, including lymphopenia.
• Invasive aspergillosis may develop before classic intensive care risk factors.
• Supports earlier fungal surveillance rather than late rescue testing.

Pulmonary cavitation as a late and self-limited complication of COVID-19 pneumonia

Osório M, Silveira M, Cureus, 2026

Relevance

• Highlights post-viral structural lung damage as a substrate for aspergillosis.

Key points

• Cavitation discussed alongside COVID-associated pulmonary aspergillosis and mucormycosis.
• Fungal risk may persist after apparent clinical recovery.

2. Allergic disease and ABPA – expanding phenotypes
Triple autoimmune overlap: rheumatoid arthritis, systemic lupus erythematosus, and hypereosinophilic asthma with ABPA features

Frontiers in Immunology, 2026 (Case Report)

Relevance

• Challenges rigid diagnostic frameworks for Allergic Bronchopulmonary Aspergillosis.
• Supports emerging views that ABPA can occur before bronchiectasis develops.

Key points

• ABPA considered despite normal chest imaging.
• Diagnosis driven by immunological and eosinophilic markers.

Diagnosis of bronchopulmonary candidiasis—refractory airway hyperresponsiveness and severe pneumonia

Zhang D et al., Frontiers in Medicine, 2026

Relevance

• Important differential diagnosis for suspected ABPA.

Key points

• Bronchopulmonary candidiasis can closely mimic ABPA.
• Normal Aspergillus serology does not exclude other fungal airway disease.

3. Rare immune defects and aspergillosis
Complete and partial forms of X-linked MCTS1 deficiency in patients with mycobacterial disease

Zhou Q et al., Journal of Human Immunity, 2026

Relevance

• Expands the list of primary immunodeficiencies associated with Aspergillus infection.

Key points

• Central nervous system aspergillosis identified as a rare but severe phenotype.
• Suggests impaired cellular immunity as the underlying mechanism.

4. Antifungal therapy – toxicity, variability, and paediatrics
Voriconazole-associated peripheral polyneuropathy: A case report

González BJ et al., Archives of Argentine Pediatrics, 2026
(No PMC full text currently available)

Relevance

• Highlights clinically important non-hepatic toxicity of azole therapy.

Key points

• Peripheral neuropathy developed during voriconazole treatment.
• Symptoms may be insidious and progressive.

RE: Factors affecting voriconazole pharmacokinetic variability in critically ill patients

Langbeen J et al., Critical Care, 2026

Relevance

• Explains why fixed dosing of voriconazole is often unsafe.

Key points

• Critical illness alters drug metabolism and clearance.
• Drug–drug interactions are common.
• Supports therapeutic drug monitoring and specialist pharmacy input.

Phase 2 clinical trial of posaconazole in paediatric invasive aspergillosis

Kang HJ et al., Antimicrobial Agents and Chemotherapy, 2026
(No PMC full text currently available)

Relevance

• Rare prospective antifungal data in children.

Key points

• Posaconazole showed acceptable safety.
• Clinical responses were encouraging in a high-risk population.

5. Diagnostics, microbiology, and co-infection
Clinical characteristics, molecular diagnosis, and drug resistance profiles of nontuberculous mycobacteria infections

Wang K et al., Clinical and Translational Science, 2026

Relevance

• Highly relevant to bronchiectasis patients where NTM and aspergillosis frequently coexist.

Key points

• Molecular diagnostics improve species identification.
• Resistance patterns complicate treatment strategies.

Impaired systemic antibody response against gut microbiota pathobionts in critical illness

Cho NA et al., Intensive Care Medicine Experimental, 2026

Relevance

• Links immune–microbiome disruption to susceptibility to Aspergillus fumigatus.

Key points

• Critical illness impairs antibody responses.
• Loss of immune balance increases infection risk.

6. Pathogenesis and basic science
Arp2/3 complex contributes to actin-dependent uptake of Aspergillus terreus conidia

Mach N et al., PLOS One, 2026

Relevance

• Improves understanding of early host–fungus interactions.

Key points

• Epithelial cells actively internalise Aspergillus conidia.
• Species differences may influence pathogenicity.

7. Environmental and One Health perspectives
Seasonal variation in Aspergillus abundance in captive penguin burrow sands

Takanobu S et al., Frontiers in Veterinary Science, 2026

Relevance

• Demonstrates dynamic environmental exposure risk.

Key points

• Clear seasonal peaks in Aspergillus burden.
• Correlates with increased disease risk.

Mycotoxins – biomonitoring method including gliotoxin

Berger M et al., MAK Collection for Occupational Health and Safety, 2026

Relevance

• Gliotoxin explored as a potential biomarker for invasive aspergillosis.

Key points

• LC-MS/MS methods validated.
• Currently research-grade rather than clinical.

Path: Start » Weekly Updates » Latest Aspergillosis & Related Research Updates (Week 4).